| Sep'19 | Sep'18 | Sep'17 | Sep'16 | Sep'15 | Sep'14 | Sep'13 | Sep'12 | Sep'11 | Sep'10 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
Net loss | |||||||||
-26,958 | -13,236 | -23,810 | -25,766 | -15,197 | -9,130 | -5,652 | -1,454 | -5,101 | 494 |
Adjustments to reconcile net loss to net cash used in operating activities | |||||||||
Discontinued operations | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Common stock issued for services | |||||||||
- | 145 | 818 | 1,754 | 635 | - | 270 | 309 | 10 | 10 |
Warrants issued for services | |||||||||
- | - | - | - | 8 | 1,177 | 335 | - | - | - |
Fair value of warrants issued for services | |||||||||
- | - | - | - | - | - | - | 632 | 123 | 129 |
Stock-based compensation | |||||||||
9,785 | 877 | 1,293 | 2,913 | 3,579 | 2,074 | 746 | 406 | 47 | 219 |
Research and development expense - license acquired | |||||||||
1,046 | - | - | - | - | - | - | - | - | - |
Research and development expense - license acquired- Ohr | |||||||||
-11,920 | - | - | - | - | - | - | - | - | - |
Change in fair value of warrant liabilities | |||||||||
492 | - | - | - | - | - | - | - | - | - |
Depreciation and amortization | |||||||||
128 | - | - | - | - | - | - | - | - | - |
Depreciation | |||||||||
- | 10 | 45 | 64 | 40 | 17 | 13 | 9 | 5 | 0 |
Amortization of intangible assets | |||||||||
- | 1,114 | 1,120 | 1,124 | 1,138 | 448 | 77 | 78 | 78 | 19 |
Impairment of intangibles | |||||||||
- | - | - | - | 338 | - | - | - | - | - |
Gain on settlement of liabilities | |||||||||
- | 1,228 | 70 | - | 40 | - | - | - | - | 19 |
Gain on settlement of accounts payable | |||||||||
- | - | - | 710 | - | - | - | - | - | - |
Loss on disposal of fixed asset | |||||||||
- | -17 | -1 | - | - | - | - | - | - | - |
Change in fair value of contingent consideration | |||||||||
- | - | - | 1,185 | -2,637 | - | - | - | - | - |
Gain (loss) on extinguishment of debt | |||||||||
- | - | - | - | - | - | - | 21 | 49 | - |
Gain on sale of asset | |||||||||
- | - | - | - | - | - | - | 0 | 70 | 0 |
Loss on derivative liability | |||||||||
- | - | - | - | - | - | -1,117 | 1,812 | -3,977 | -1,480 |
Equity in losses on equity method investment | |||||||||
- | - | - | - | -103 | -10 | - | - | - | - |
Non-cash amortization on convertible notes | |||||||||
94 | - | - | - | - | - | - | - | - | - |
Non-cash interest expense on convertible notes | |||||||||
21 | - | - | - | - | - | - | - | - | - |
Gain on sale of intangible assets | |||||||||
- | 460 | - | - | - | - | - | - | - | - |
Loss on Impairment of goodwill and intangible assets | |||||||||
- | 6,054 | - | - | - | - | - | - | - | - |
Changes in operating assets and liabilities | |||||||||
Other prepaid expenses and current assets | |||||||||
386 | -310 | -657 | 64 | -7 | -105 | -236 | -105 | 82 | -34 |
Long-term prepaid insurance | |||||||||
338 | - | - | - | - | - | - | - | - | - |
Accounts payable | |||||||||
962 | - | - | - | - | - | - | - | - | - |
Accrued expenses and other current liabilities | |||||||||
385 | - | - | - | - | - | - | - | - | - |
Other receivables and other current assets | |||||||||
- | - | - | - | - | - | - | 184 | -119 | -65 |
Accounts payable and accrued expenses | |||||||||
- | -3,096 | 654 | 3,511 | 1,331 | -63 | 165 | 20 | 12 | 203 |
Acquisition of SKS Ocular's assets | |||||||||
- | - | - | - | - | 3,500 | - | - | - | - |
Net cash used in operating activities | |||||||||
-2,845 | -9,492 | -19,290 | -15,985 | -10,692 | -5,360 | -2,689 | -1,753 | -1,004 | -521 |
Cash flows from investing activities | |||||||||
Purchase of laboratory and office equipment | |||||||||
455 | - | - | - | - | - | - | 33 | 0 | 25 |
Cash acquired in connection with Acquisition of Ohr | |||||||||
752 | - | - | - | - | - | - | - | - | - |
Payment of transaction costs for Acquisition of Ohr | |||||||||
884 | - | - | - | - | - | - | - | - | - |
Payment of transaction costs for license acquired | |||||||||
43 | - | - | - | - | - | - | - | - | - |
Investment in joint venture | |||||||||
- | - | - | - | 100 | 13 | - | - | - | - |
Purchase of property and equipment | |||||||||
- | - | 4 | 14 | 184 | 1 | - | - | - | - |
Proceeds from sale of property, equipment and intangible assets | |||||||||
- | 528 | 93 | - | - | - | - | 0 | 70 | 0 |
Cash paid for license acquired | |||||||||
54 | - | - | - | - | - | - | 0 | 0 | 0 |
Discontinued operations | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Net cash used in investing activities | |||||||||
-685 | 528 | 88 | -14 | -284 | -3,514 | - | -33 | 70 | -25 |
Cash flows from financing activities | |||||||||
Payment for warrant redemption | |||||||||
141 | - | - | - | - | - | - | - | - | - |
Principal payment of financed insurance | |||||||||
90 | - | - | - | - | - | - | - | - | - |
Proceeds from issuance of common stock in pre-acquisition financing, net of issuance costs | |||||||||
8,268 | - | 19,580 | 0 | 26,582 | 16,876 | - | 1,100 | 1,050 | 0 |
Proceeds from issuance of common stock in private placement financing, net of issuance costs | |||||||||
4,957 | - | - | - | - | - | - | - | - | - |
Proceeds from issuance of convertible notes | |||||||||
600 | - | - | - | - | - | - | - | - | - |
Proceeds from issuance of common shares for services | |||||||||
-1 | - | - | - | - | - | - | - | - | - |
Proceeds from prefunded warrant | |||||||||
0 | - | - | - | - | - | - | - | - | - |
Repurchase of common stock | |||||||||
0 | - | - | - | - | - | - | - | - | - |
Proceeds from the sale of preferred stock and warrants | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Proceeds from warrants exercised for cash | |||||||||
- | 270 | 118 | 26 | 80 | 260 | 5,251 | 2,902 | 0 | 1,005 |
Proceeds from related party payables | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Repayments of related party payables | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Proceeds from short-term notes payable | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 64 |
Repayments of short-term notes payable | |||||||||
- | 356 | 242 | 176 | 208 | 164 | 71 | 52 | 17 | 46 |
Repayment of convertible debentures | |||||||||
- | - | - | - | - | - | - | 0 | 51 | 398 |
Net (used in) provided by financing activities | |||||||||
13,595 | -86 | 19,456 | -150 | 26,454 | 16,972 | 5,180 | 3,949 | 981 | 623 |
Net (decrease) increase in cash and cash equivalents | |||||||||
10,064 | - | - | - | - | - | - | - | - | - |
NET CHANGE IN CASH | |||||||||
- | -9,050 | 254 | -16,150 | 15,476 | 8,097 | 2,490 | 2,162 | 47 | 76 |
Cash paid for interest | |||||||||
3 | 10 | 8 | 6 | 5 | 5 | 4 | 1 | 24 | 31 |
Subscriptions receivable from exercise of warrants | |||||||||
- | - | - | 118 | - | - | - | - | - | - |
Non-cash investing and financing activities: | |||||||||
Issuance of common stock for research and development expense-licenses acquired | |||||||||
844 | - | - | - | - | - | - | - | - | - |
Issuance of common stock for conversion of debt | |||||||||
944 | - | - | - | - | - | - | - | - | - |
Issuance of common stock for conversion of accrued interest | |||||||||
21 | - | - | - | - | - | - | - | - | - |
Issuance of common stock for the cashless exercise of warrant | |||||||||
429 | - | - | - | - | - | - | - | - | - |
Insurance financed through note payable | |||||||||
213 | - | - | - | - | - | - | - | - | - |
Issuance of common stock and options for acquisition of Ohr | |||||||||
11,776 | - | - | - | - | - | - | - | - | - |
Income Taxes | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Financing of insurance premiums through issuance of short term notes | |||||||||
- | 323 | 261 | 215 | 212 | 194 | - | 74 | 0 | - |
Settlement of contingent consideration | |||||||||
- | - | - | 3,425 | - | - | - | - | - | - |
Stock cancellation related to employee resignation | |||||||||
- | - | 0 | - | - | - | - | - | - | - |
Conversion of preferred for common stock | |||||||||
- | - | - | - | - | 0 | 0 | 0 | - | - |
Noncash exercise of options and warrants | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Common stock issued to acquire intangible assets | |||||||||
- | - | - | - | - | 10,180 | 0 | - | - | - |
Reclassification of derivative liability to permanent equity | |||||||||
- | - | - | - | - | - | 1,886 | 3,454 | 0 | - |
Deferred offering costs, accrued but not yet paid | |||||||||
- | - | - | - | - | - | 63 | - | - | - |
Common stock issued to settle accounts payable | |||||||||
- | - | - | - | 50 | 50 | 0 | 0 | - | - |
Transfer of investment for dividends payable | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Purchase of patents for debenture | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Conversion of debenture | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 10 |
Options issued to settle accounts payable | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 3 |